Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on May 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results covered quarter ended March 31, 2026.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing financial results and corporate updates
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.